Skip to main content

Do you work with FFPE tissue? MT Group sites have collected thousands of FFPEs for translational studies across indications, therapies, tissue types, and geographies.   We’ve collected both common cases as well as rare ones such as:

  • Metastatic bladder cancer patients who had failed one or more systemic therapy regimens before tissue collection
  • Castration-resistant prostate cancer patients then went on to develop metastatic disease
  • Cancer patients that were collected after receiving immuno-oncology (IO) therapeutics
  • Diffuse large B-cell lymphoma (DLBCL) patients that were collected both before R-CHOP therapy and after / on R-CHOP therapy

For all of these collections, “MT Level” clinical metadata is the norm, enabling researchers to compare their bench results with clinical profiles.

Email Us

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
How can we help?*
Name*
Address
Blood and tissue for early detection, MRD, and Tx guidance assays. Meet us at AMP Nov 10–14 to discuss your study!
SEE US AT AMP · BOOTH 2111
Biospecimens for Liquid Biopsy
Current Topic
Small Cell Lung Cancer (SCLC) FFPE